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Background: SYT-SSX is the oncogene associated with synovial sarcoma (SS), a stem cell disease. SYT-SSX is
thought to be responsible for sarcoma initiation and development. It interacts with components of Polycomb and
SWI/SNF complexes, the two epigenetic controllers that maintain the heritable status of differentiation-specific
genes in the stem/progenitor cell. Through these associations SYT-SSX is thought to alter gene expression
programs by epigenetic mechanisms. Recently, we reported that SYT-SSX2 reprograms mesenchymal stem cells and
myoblasts by dictating their commitment to the neural lineage while disrupting their normal differentiation. This
reprogramming was due to the direct occupancy of proneural genes by the SYT-SSX2 nuclear complex. To gain a
clear understanding of SYT-SSX2 control of gene expression networks, we conducted a thorough genome-wide
analysis to determine the mechanism of its recruitment and identify signature sets of epigenetic markers that
would predict its targeting and transcriptional activity.
Results: SYT-SSX2 was recruited to distinct loci across all chromosomes, and an overwhelming number of
Polycomb-modified sites enriched with the trimethylated histone H3 on lysine 27 (H3K27me3) formed the main
recruiting module for SYT-SSX2. Not all SYT-SSX2/H3K27me3-occupied genes had altered expression, denoting the
requirement for additional signals upon oncogene binding. Differential binding and epigenetic patterns
distinguished upregulated and downregulated genes. Most activated genes had SYT-SSX2 sites enriched with
H3K27me3 within their body or near their transcription start site (TSS) whereas a majority of downregulated genes
were characterized by SYT-SSX2/H3K27me3-rich regions at long-range, or by modifications associated with
transcription activation within the gene body or near the TSS. Hierarchical and functional clustering identified
H3K27me3 as the dominant epigenetic marker associated with SYT-SSX2 binding and gene expression. Notably, this
analysis revealed a cluster of upregulated neuronal genes densely covered by H3K27me3, consistent with
programming toward the neural lineage by SYT-SSX2 observed previously.
Conclusions: The data analysis revealed that Polycomb complexes or their modified chromatin and their stably
silenced differentiation programs seem to be the main target for SYT-SSX2, suggesting that their perturbation is at
the center of tumorigenesis driven by the oncogene. Further research into this mechanism is crucial to the full
understanding of SS biology.* Correspondence: josiane.eid@vanderbilt.edu
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The SYT-SSX oncogene is the product of a recurrent
t(X;18)(p11.2;q11.2) chromosomal translocation that char-
acterizes synovial sarcoma (SS), a high grade, soft tissue
cancer that typically arises in adolescents and young
adults. Because synovial sarcoma tumors are known to de-
velop in multiple sites of the body (with higher incidences
near the joints of the lower extremities), it is believed that
the disease originates in a primitive stem cell capable of
differentiation into multiple lineages [1,2]. Recent studies
have supported this hypothesis since human synovial sar-
coma cells displayed features of multipotent stem cells
whose differentiation capacity was deregulated by the
oncogene [3,4], and transgenic mouse modeling revealed
that tumors recapitulating SS features developed in pre-
cursors of the muscle lineage but not in more differen-
tiated myocytes upon expression of the oncogene [5].
SYT-SSX formation is the primary event in synovial sar-
coma, and its prevalent expression in the SS tumors impli-
cates it in cancer initiation and progression [1,2].
Determining the molecular function of SYT-SSX is there-
fore essential for unraveling the mechanism of tumorigen-
esis in synovial sarcoma.
Wild type SYT (SYnovial sarcoma Translocated) and
SSX (Synovial Sarcoma X) are nuclear proteins believed
to function in the regulation of gene expression. SYT is
required for early embryonic development [6-8] and is
widely expressed in adult tissues. It lacks known DNA-
binding motifs [9] and forms direct associations with key
transcription modulators, including the p300 acetyl
transferase (HAT; [10]), the SWI/SNF chromatin-
remodeling complex ATPase, Brg1/Brm [11,12], and the
repressor complex component, Sin3A [13]. All three
SYT-binding proteins are known epigenetic controllers,
thus these interactions are thought to regulate the coac-
tivating function of SYT.
In contrast, the SSX genes encode a nine-member
family of transcriptional corepressors located on the X
chromosome whose physiological functions remain un-
clear [14]. Like SYT, SSX proteins lack a DNA binding
domain; therefore, they may also exert their function via
protein-protein interactions. It was revealed that SSX1
and SSX2 colocalize with Polycomb group (PcG) com-
plexes through the SSXRD (SSX Repressor Domain), a
highly conserved domain responsible for the bulk of its
repressor activity [11,15-19]. Additional studies suggest
that SSX proteins may also be targeted through direct
interactions with chromatin or by binding to sequence-
specific transcription factors [20,21].
When SYT-SSX forms, it retains almost the entire
coding sequence of SYT, hence binding to the coactiva-
tors p300 and Brg1-SWI/SNF [11,17]. Most often, the
fusion occurs with the C-terminal half of either SSX1 or
SSX2 [1,2] and the association with silencing Polycombcomponents is preserved, creating a transcriptional im-
balance: the naturally antagonistic Polycomb and SWI/
SNF complexes which function in concert during devel-
opment to coordinate multipotency and differentiation
[22] are brought to the same genomic sites by the
mutant protein. The predicted outcome is a global alter-
ation in the nuclear programming of the SYT-SSX-
expressing cell, leading to tumor initiation. Both
aberrant silencing and activation of target genes via
Polycomb activity manipulation occur due to SYT-SSX.
SYT-SSX2 associates with the promoter of the tumor
suppressor gene, EGR1, and recruits Polycomb proteins
to this locus causing its repression [23]. SYT-SSX2 ex-
pression also leads to aberrant transcriptional derepres-
sion of several Polycomb targets by enhancing
degradation of the Polycomb Repressive Complex 1
(PRC1) core component, Bmi1 [24]. The capacity to
alter the epigenetic status of target genes also implies
the persistence of the altered program in the resulting
tumor. The activities of both Brg1-SWI/SNF and Poly-
comb maintain the expression status of genes when the
initiating signal, either activation or repression, is gone
[25]. This suggests that SYT-SSX could dominantly re-
program the cell through modulation of epigenetic tran-
scriptional control.
Recently, in an effort to elucidate the initial steps of
cellular transformation by SYT-SSX2, we adopted two
differentiation systems, the C2C12 myoblasts and
human bone marrow-derived mesenchymal stem cells
(hBMMSCs). This choice was based on the desire to
conduct the SYT-SSX2 studies in undifferentiated sys-
tems that were physiologically close to the two cellular
backgrounds in which SS tumors developed [4,5]. In a
comparative microarray analysis, we were struck by the
predominance of upregulated proneural genes in both
cell lines expressing SYT-SSX2 [26]. To examine how
SYT-SSX2 dictated the proneural lineage, we set out to
identify the specific gene loci to which the oncogene was
recruited in the C2C12 myoblasts, by ChIPSeq (Chroma-
tin Immunoprecipitation-sequencing) analysis. Correl-
ation of SYT-SSX2 occupancy with transcription
regulation within a 10Kb window from gene transcrip-
tion start sites (TSS) revealed that an extensive array of
neural genes was directly occupied by the oncogene in
their proximal regulatory regions [26]. This result
strongly suggested that SYT-SSX2 dictated commitment
to the neural lineage through its physical recruitment to
genes involved in diverse aspects of neural function and
growth. Differentiation analysis further supported the
dominant reprogramming by SYT-SSX2. Notably, while
SYT-SSX2 reprogrammed the stem/progenitor cells to
the neural lineage, it disrupted their normal differenti-
ation, as the BMMSCs and C2C12 cells were unable to
undergo adipogenesis and myogenesis, respectively [26].
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tion by SYT-SSX2 of known controllers of stem cell
growth and lineage-specification: the Wnt, fibroblast
growth factor (FGF), sonic hedgehog (Shh), NOTCH,
and transforming growth factor/bone morphogenetic
protein (TGFβ/BMP) pathways. Notably, direct targeting
and activation of the FGF receptor gene, Fgfr2, by SYT-
SSX2 were responsible for the induction of the neural
phenotype in the stem cells [26].
These studies uncovered a dominant function of the
SYT-SSX2 oncogene in redirecting differentiation of the
mesenchymal stem cells. They also revealed the activa-
tion of an autocrine signaling network that would render
the stem cell autonomous and facilitate its transform-
ation. Remarkably, the SYT-SSX2-driven effects were
not only occurring in the C2C12 myoblasts and the
human BMMSCs, but they were also evident in human
SS tumor cells, revealing the persistent activation of
SYT-SSX function throughout the life of the cancer [26].
These findings strongly suggest that aberrant repro-
gramming forms the basis of SYT-SSX transforming ac-
tivity. To begin to understand its mechanism we decided
to closely examine the nature of SYT-SSX2 recruitment
to genomic loci. Recent evidence suggests that co-
regulated gene subsets are characterized by common
histone modification signatures. It has been shown that
genes participating in similar functional pathways with
identical expression patterns are marked by the same
complement of histone modifications in yeast and
mouse myoblasts [27,28], so combinations of markers
may serve as a signature for transcriptional regulators
denoting the coordinated expression of these genes.
Since SYT-SSX2 interacts with epigenetic controllers, we
sought to determine if a signature set of epigenetic mar-
kers associated with SYT-SSX2 occupancy exists, and to
ascertain whether this specific set of markers could pre-
dict transcriptional activation or repression mediated by
the oncogene. To answer these questions, we decided to
conduct an in-depth analysis of the genome-wide bind-
ing of SYT-SSX2 and define the chromatin state of the
genomic loci that attract the translocation.
We observed that SYT-SSX2 association with the
genome is non-random, and it localizes to distinct
regions. However, our most significant finding was the
discovery that SYT-SSX2 occupies trimethylated histone
H3 lysine 27- (H3K27me3) labeled regions within or
near over 70% of positively regulated and 40% of nega-
tively regulated genes. H3K27me3 represents the modi-
fication characteristic of Polycomb-silenced genes, and
its prominent association with SYT-SSX2 supports a role
for the oncogene in the re- activation of Polycomb-
silenced genes. These data suggest that Polycomb com-
plexes serve as a recruitment module for the fusion
protein. An additional subset of downregulated SYT-SSX2 target genes are characterized by association of
the protein with histone modifications that correlate
with transcriptional activation. Taken together, there
are at least 2 mechanisms of SYT-SSX2 recruitment to
target genes: one dependent on PcG proteins and the
other Polycomb-independent.
These results provide a fundamental basis for future re-
search that will unravel the effect of SYT-SSX2 on the
silenced differentiation programs stabilized by Polycomb
and how their disruption leads to cellular transformation.
Results
SYT-SSX2 binding across the genome is heterogeneous
and nonrandom
As an initial step toward elucidating the mechanism of
gene expression programming by SYT-SSX2 in mesen-
chymal precursor cells, we decided to start by examining
its landing pattern in the genome. To generate a global
picture of the SYT- SSX2 binding sites throughout the
genome, we relied on the ChIPSeq experiment per-
formed in C2C12 myoblasts expressing the oncogene
[26]. The ChIPSeq analysis led to the identification of
nearly 53,000 genomic regions (or peaks) bound by the
SYT- SSX2 nuclear complex. The specificity of SYT-
SSX2 peaks was confirmed by a maximum false discov-
ery rate of 2.8% [26]. To derive the distribution pattern
of SYT- SSX2 binding, we performed a sliding window
analysis in which each chromosome was subdivided into
500kb bins, and the number of SYT-SSX2 peaks in each
bin was tabulated. SYT-SSX2 displayed heterogeneous
binding among the chromosomes as a whole and along
each chromosome individually (Figure 1, Additional file
1). Nearly 20% of the binding sites (9,750) are located on
the X chromosome, whereas chromosome 3 has 674
binding sites (1.3%; Table 1). Interestingly, areas with
high levels of binding are located at chromosome ends,
notably on chromosomes 2, 4, 11, 15, and X (Figure 1,
Additional file 1). This trend is also seen to a lesser de-
gree on chromosomes 7, 8, 12, and 16-19 (Additional file
1). Binned binding sites appear to cluster loosely into 3
density categories: low, medium, and high. Low-density
clusters are similar to the cluster centered around 5Mb
on chromosome 2 and contain bins with <100 peaks
(Figure 1, arrowhead). Medium- density clusters contain
1-2 bins with 100-200 peaks surrounded by other bins
with less than 100 peaks like the clusters centered at
28Mb or 74Mb on chromosome 2 (Figure 1, arrows).
The cluster centered at 179Mb on chromosome 2
(Figure 1, double arrowhead) is an example of a high-
density cluster which contains bins with >200 peaks
with nearby bins containing >100 peaks. These data
indicate that SYT-SSX2 recruitment to target loci is
nonrandom and displays a preference for specific
chromosomal regions.
Figure 1 Chromosomal distribution of SYT-SSX2 peaks. Diagrams of chromosomes 2, 4, and 15. Chromosomes were subdivided into 500kb
bins, and the number of SYT-SSX2 ChIPSeq peaks was tabulated for each bin. Black bars represent individual bins, and the height of each bar is
proportional to the number of SYT-SSX2 peaks contained within that window. Scale bar shown represents a distance of 10MB. Red and green
stars, respectively, depict the location of upregulated and downregulated genes determined by microarray analysis that could be annotated to
SYT-SSX2 occupied regions.
Table 1 Distribution of SYT-SSX2 peaks per chromosome
Chromosome Number of peaks Percentage of peaks Chromosome Number of peaks Percentage of peaks
1 1,651 3.1 11 3,712 7.0
2 5,311 10.0 12 2,573 4.9
3 674 1.3 13 1,145 2.2
4 6,309 11.9 14 1,493 2.8
5 4,146 7.8 15 3,202 6.0
6 1,913 3.6 16 798 1.5
7 1,846 3.5 17 1,842 3.5
8 2,759 5.2 18 836 1.6
9 1,466 2.8 19 801 1.5
10 765 1.4 X 9,750 18.4
Chromosomes were subdivided into 500kb bins, and the number of SYT-SSX2 ChIPSeq peaks was tabulated for each bin.
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marker histone H3 lysine 27 trimethylation
After enumerating its genome-wide locations, we asked
whether SYT-SSX2 is recruited to specific loci by dis-
tinct epigenetic modules. Identifying the determinants of
SYT-SSX2 recruitment would reveal crucial details con-
cerning the mechanism by which it modulates transcrip-
tion. To determine if SYT-SSX2 binding might be
associated with specific epigenetic markers, previously
published genome-wide datasets for histone modifica-
tions and RNA polymerase II binding sites (PolII) [28] in
naïve unstimulated C2C12 myoblasts were intersected
with our SYT-SSX2 dataset allowing us to determine the
nature of the stable epigenetic landscape to which SYT-
SSX2 was recruited. Positions of histone modification
enrichment and protein binding are reported as chromo-
somal positions, thus areas where the datasets intersect
can be determined computationally. For our study, we
looked for regions that overlap≥ 1 nucleotide since SYT-
SSX2 interacts with large protein complexes, and a
1-base overlap suggests close proximity to a given modi-
fication. By this method, we found quite strikingly that
22,537 SYT-SSX2-occupied regions (42.5%) overlapped
with trimethylated histone H3 lysine 27 (H3K27me3;
Table 2, Figure 2), the modification associated with Poly-
comb repressive complexes. This represents approxi-
mately 13% of the total H3K27me3- enriched regions in
the genome of the C2C12 myoblasts (Table 3), indicating
that at the global level, SYT-SSX2 is preferentially tar-
geted to a subset of Polycomb-regulated genes. Overlap
with other histone modifications and PolII was not as ex-
tensive (Figure 2, Tables 2 and 3). The next highest
amount of overlap was seen with monomethylated his-
tone H3 lysine 4 (H3K4me1: 3,498 peaks, 6.6%) followed
by acetylated histone H3 lysine 18 (H3K18Ac: 1,961
peaks, 3.7%). This accounts for 1.3% and 0.99% of the
total number of regions marked by H3K4me1 and
H3K18Ac, respectively (Table 3), indicating that SYT-
SSX2 is associated with only a small subset of locations
labeled by either of these modifications. It has been sug-
gested that these marks identify enhancer elements [29]
highlighting another possible mechanism by which SYT-
SSX2 may affect gene expression.Table 2 Overlap of SYT-SSX2 peaks with epigenetic markers
Modification Number of peaks Percent of peaks Modi
H3K4me1 3498 6.6 H3
H3K4me2 816 1.54 H3
H3K4me3 905 1.71 H3K
H3K27me3 22,537 42.5 H4
PolII 1034 1.95 H2
The number and percent of peaks are relative to the total number of SYT-SSX2 bindThe prominence of SYT-SSX2 occupying regions
enriched in H3K27me3 led to the question of their loca-
tion relative to known genes. It has been shown that
Polycomb complexes can mediate both short- and long-
range control of gene expression [30,31], thus we deter-
mined the location of the overlapping regions between
SYT-SSX2 and H3K27me3 relative to known genes.
3,692 genes could be annotated to SYT- SSX2/
H3K27me3 intersecting areas, and of these, 45.6% of the
peaks were located within the gene itself (Table 4).
Nearly 900 genes had overlapping sites from 0-5kb up-
stream of gene transcription start sites (TSS), and to-
gether with the genes marked by SYT-SSX2/H3K27me3
regions within the coding sequence, they account for
50% of the total SYT-SSX2-Polycomb labeled genes
(Table 4). These data strongly indicate that SYT-SSX2
interacts with Polycomb complexes that function at
short-range. Altogether, these data illustrate that SYT-
SSX2 may be preferentially targeted to specific genomic
locations through interaction with Polycomb complexes
and/or their associated histone modifications. This is
consistent with previous studies in which SYT-SSX2 was
able to associate with Polycomb proteins [23,24]. More-
over, SYT-SSX2 may function through the modulation of
Polycomb activity via short-range interactions.
Differential patterns of SYT-SSX2 binding are associated
with its transcriptional activity
We next inquired whether the pattern of SYT-SSX2 oc-
cupancy and its global recruitment to distinct epigenetic
modifications correlated with its regulatory effects on
gene transcription. We addressed this question by inter-
secting the ChIPSeq-derived SYT-SSX2 genomic sites
with the gene profile microarray of C2C12 myoblasts
expressing the oncogene [26]. By including differentially
regulated genes with SYT- SSX2 binding sites at any dis-
tance upstream of the TSS or within the gene body, we
identified a total of 460 upregulated and 280 downregu-
lated genes associated with SYT-SSX2 peaks. These
genes were mapped to their relative chromosomal loca-
tion to determine if there was an association between
the number of SYT-SSX2 peaks and gene activity. As a






ing sites (total = 52,992).
Figure 2 Overlap of SYT-SSX2 peaks with epigenetic markers.
Datasets that identified regions of enrichment for histone
modifications and PolII binding [28] were compared with the
locations of the SYT-SSX2 peaks using the Galaxy analysis suite to
determine sites of overlap. The bar graph shows the percent of SYT-
SSX2 peaks that overlap with 10 epigenetic markers. Ubiquitylated
histone H2 lysine 120 (H2UB) is a marker for transcription elongation.
Mono, di, and trimethylated histone H3 lysine 4 (H3K4me1,
H3K4me2, H3K4me3), as well as acetylated histone H3 lysine 9
(H3K9Ac), acetylated histone H3 lysine 18 (H3K18Ac), acetylated
histone H4 lysine 12 (H4K12Ac), and RNA Polymerase II (PolII) all
mark gene promoters and enhancers. Trimethylated histone H3
lysine 36 (H3K36me3) is a marker for active transcription in gene
bodies. Trimethylated histone H3 lysine 27 (H3K27me3) is the
Polycomb-specific modification associated with chromatin silencing.
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dots, Additional file 1) while high-density clusters most
often corresponded with positively regulated genes
(Figure 1, red dots, Additional file 1). Interestingly,
there does not appear to be a correlation between the
density of SYT- SSX2 binding and the number of genes
that are either up- or downregulated. On chromosome 4,
a high-density cluster is centered at 153Mb, however
only 2 genes (1 upregulated and 1 downregulated) are
associated with this area (Figure 1, box).
Conversely, on chromosome 15, a region dense with
activated genes centered at 102Mb most closelyTable 3 Coverage of epigenetic markers by SYT-SSX2






Columns 2 and 5 show the total number of SYT-SSX2 peaks overlapping with each
SYT-SSX2 peaks cover the total genomic area of each modification.corresponds to a low-medium density cluster (Figure 1,
oval). Taken together, these data indicate that SYT-SSX2
binding correlates with alterations in gene activity; how-
ever, not all binding sites are associated with changes in
gene expression, suggesting that SYT-SSX2 may have
additional functions in the nucleus. These results are in
line with a previous observation that the majority of
SYT-SSX2 peaks are located at distances greater than
50kb from gene TSS [26] indicating that the oncogene
may be involved in chromatin structure regulation,
thereby affecting gene expression at long range.
We then narrowed our focus to the study of differen-
tially regulated genes to determine whether SYT-SSX2
binding patterns could distinguish gene activation from
gene repression. Interestingly, the distribution of SYT-
SSX2 binding sites upstream of the TSS was markedly
different depending on whether a gene was positively or
negatively regulated by oncogene expression. Overall,
more than half of the upregulated genes bound by SYT-
SSX2 (53.9%) have at least 1 peak within a window from
0-20kb upstream of the TSS. This number decreased
with increasing distance (Figure 3, top panel). In con-
trast, 21.4% of the genes that are downregulated and
bound by SYT-SSX2 have peaks within a 0-20kb window
upstream of the TSS. This percentage increases with in-
creasing distance, peaks from 50-100kb then decreases
at distances between 100-150kb and 150-200kb (Figure 3,
top panel). These data suggest that SYT-SSX2-associated
transcriptional activation is correlated with binding at
close range whereas transcriptional repression associates
with binding at farther distances.
SYT-SSX2 recruitment to Polycomb-modified chromatin
and enhancer elements is associated with its
transcriptional activity
Recently, it has been shown that genes within specific
functional groups can be distinguished by the pattern of
histone modifications surrounding them. This suggests
that genes within a distinct pathway have a specific epi-
genetic signature that allows them to be recognized by
particular activating and/or repressing factors. In this
way, the cell can simultaneously regulate a cohort of






modification. Numbers in columns 3 and 6 represent the extent to which the
Figure 3 Differential pattern of binding between upregulated
and downregulated genes targeted by SYT-SSX2. 425
upregulated and 223 downregulated genes were bound by SYT-
SSX2 ranging from within the gene body up to 200Kb upstream of
the TSS. Top panel shows the percentage of genes that are
occupied by SYT-SSX2 within given distance windows. Bottom panel
depicts a bar graph showing the percentage of genes for which the
associated SYT-SSX2 occupied regions overlap with the given
epigenetic markers. Red bars represent upregulated genes, and
yellow bars signify downregulated genes.
Table 4 Distribution of SYT-SSX2 peaks overlapping with
H3K27me3 relative to gene transcription start sites
Distance from TSS Number of genes Percent of genes
In gene 1682 45.6
0-5 kb 872 23.6
In-5 kb 1874 50.8
0-20 kb 1672 45.3
20-50 kb 1524 41.3
>50 kb 1917 51.9
Regions of SYT-SSX2 binding intersecting with regions of H3K27me3 (≥ 1
nucleotide) were annotated to the closest TSS. A total of 3,692 genes were
found to be associated with SYT-SSX2/H3K27me3 in this manner. Percent of
genes refers to the number of genes with a SYT-SSX2/H3K27me3 overlapping
region over 3,692.
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subsets of genes that were differentially regulated by
SYT-SSX2, overlap of SYT-SSX2 peaks with histone
modifications at the gene loci was determined. Seventy-
two percent (72%) of the upregulated genes and 43.6%
of the downregulated genes bound by SYT-SSX2 have
associated peaks that overlap with H3K27me3 (Figure 3,
bottom panel) corroborating previous reports that the
fusion protein is targeted to Polycomb-regulated genes.
Surprisingly, 43.6% of the upregulated genes and 33.6%
of the downregulated genes have SYT-SSX2 peaks that
overlap with H3K4me1. This is significant considering
that the overlap with H3K4me1 occurs with only 6.6% of
the total SYT-SSX2 peaks overall. It also means that
SYT-SSX2 binding to enhancer elements may be a spe-
cific feature for genes destined for altered expression.
Since this modification labels enhancer elements [29],
the association of SYT-SSX2 with these sites as well as
Polycomb target sites suggests that SYT-SSX2 may effect
transcription by modulating both enhancer and Poly-
comb function.
Distinct patterns of chromatin marks characterize genes
occupied and regulated by SYT-SSX2
We next decided to examine more closely the epigenetic
landscape around the genes that were differentially regu-
lated by SYT-SSX2. Our goal was to generate a model
for SYT-SSX2 recruitment that would provide important
leads into its mode of gene expression alteration, and
determine whether distinct mechanisms are used by the
fusion protein to activate or repress genes. As a first
step, we tabulated the number of SYT-SSX2 peaks for
each gene within a particular expression category (posi-
tively or negatively regulated) that overlapped with his-
tone modifications, PolII binding, and DNA methylation
in 5kb windows up to 50kb upstream of TSS and within
the gene. We limited our analyses to this distance be-
cause of the association of SYT-SSX2 with Polycomb-
marked regions at close-range relative to gene TSS andbecause of the difficulty in definitively assigning func-
tional significance to binding sites at farther distances.
For this analysis we also only characterized genes that
had SYT-SSX2 binding sites that overlapped with at least
1 epigenetic marker and identified 314 upregulated and
110 downregulated genes by this criterion. Of these
upregulated genes, 50% had overlapping sites between
the fusion protein and H3K27me3 (Table 5). This per-
centage decreases with increasing distance consistent
with the trend described above with respect to all genes
with SYT-SSX2/H3K27me3 intersecting regions. Also
consistent with trends described above, the second most
abundant overlap occurred between SYT-SSX2 and
H3K4me1 within the gene body. Association between
SYT- SSX2 and other histone modifications, particularly
those related to transcriptional activation (but not
Table 5 Distribution of SYT-SSX2-overlapping epigenetic markers relative to transcription start sites of upregulated
genes
Marker In 0-5 5-10 10-15 15-20 20-25 25-30 30-35 35-40 40-45 45-50
DNA me 9.55 4.46 0.32 0.96 0.32 0 0 0.64 0.32 0.64 0.64
H3K4me1 18.8 5.10 2.23 5.41 5.73 2.55 6.37 3.82 4.46 4.46 5.73
H3K4me2 8.28 5.10 0.32 1.27 0.64 0.64 0.96 0.32 0.96 0.96 0.64
H3K4me3 8.60 4.14 0.64 1.27 0.32 0.64 0.64 0.32 0.64 1.27 0.96
H3K27me3 50.0 31.2 29.3 25.7 23.9 24.5 23.6 21.3 21.3 22.0 19.4
H3K9Ac 5.10 0.64 0.32 0.64 0 0.32 0.96 0.32 0.64 1.91 0.64
H3K18Ac 9.24 2.23 1.91 2.23 2.55 2.55 2.55 2.23 3.82 4.78 3.50
H3K36me3 2.87 0 0 0.32 0.64 0.32 0.32 0.96 0 0.96 0.32
H4K12Ac 7.32 1.27 0.64 1.59 1.27 0.96 0.64 1.27 1.59 1.91 0.96
H2BUb 1.27 0 0 0.32 0.32 0.64 0.32 0.64 0 0.32 0
PolII 10.2 3.18 1.59 1.91 1.27 1.27 1.27 1.59 1.27 2.23 2.55
Percentages are relative to the total number of upregulated genes with SYT-SSX2 peaks that overlap any epigenetic marker from 0-50kb upstream of the TSS and
including the gene body (total = 314). Numbers in first row represent distances measured in kilobases.
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though to a much lesser extent than either H3K27me3
or H3K4me1 (Table 5). In general, the number of genes
in which SYT-SSX2 associated with these other modifi-
cations decreased with increasing distance, although
there are a few exceptions. Of the negatively regulated
genes, the highest levels of overlap were also seen in the
gene body and occurred with H3K4me1 and H3K27me3
(Table 6). For H3K4me1, the number of genes with
intersection of this mark with SYT-SSX2 occupancy gen-
erally decreases with increasing distance upstream of the
TSS; however, from 25-30kb and 40-45kb the number of
genes with SYT-SSX2/H3K4me1 regions was increased
relative to the surrounding windows (Table 6). For
H3K27me3, a slightly different pattern is seen. The
number of genes with SYT-SSX2/H3K27me3 sitesTable 6 Distribution of SYT-SSX2-overlapping epigenetic mar
genes
Marker In 0-5 5-10 10-15 15-20
DNA me 7.27 4.55 0.91 0.91 0
H3K4me1 23.6 8.18 9.09 8.18 5.45
H3K4me2 17.3 10.0 3.64 1.82 1.82
H3K4me3 17.3 10.9 2.73 3.64 1.82
H3K27me3 22.7 3.64 10.0 7.27 7.27
H3K9Ac 14.6 9.09 4.55 3.64 2.73
H3K18Ac 17.3 3.64 7.27 6.36 4.55
H3K36me3 8.18 0.91 1.82 1.82 0.91
H4K12Ac 12.7 9.09 3.64 7.27 1.82
H2BUb 7.27 0 1.82 0.91 0
PolII 18.2 10.0 3.64 0.91 4.55
Percentages are relative to the total number of downregulated genes with SYT-SSX
and including the gene body (total = 110). Numbers in first row represent distancesdecreases dramatically from 0- 5kb but increases with
increasing distance upstream of the TSS (Table 6). With
downregulated genes, SYT-SSX2 also appears to associ-
ate with modifications related to active transcription.
Regions enriched in H3K4me2, H3K4me3, H3K9Ac,
H3K18Ac, H4K12Ac, and PolII occupancy overlap with
SYT-SSX2 binding sites in over 10% of the downregu-
lated genes, and markers associated with transcriptional
elongation (H3K36me3 and H2BUb) overlap with SYT-
SSX2 sites in more than 5% of the downregulated genes
(compared with less than 3% of the upregulated genes).
In summary, SYT-SSX2 associates with epigenetic mar-
kers, particularly H3K27me3 and H3K4me1. Most of the
upregulated genes in this analysis are marked by
H3K27me3, and SYT-SSX2 appears to bind close to the
TSS. In contrast, SYT-SSX2 occupies H3K4me1- orkers relative to transcription start sites of downregulated
20-25 25-30 30-35 35-40 40-45 45-50
0.91 0.91 0 0 0.91 2.73
3.64 8.18 5.45 3.64 8.18 1.82
3.64 3.64 0 0 4.55 2.73
4.55 2.73 0.91 0.91 3.64 6.64
7.27 12.7 8.18 11.8 15.5 16.4
1.82 1.82 0 0 2.73 1.82
2.73 3.64 0 4.55 3.64 3.64
2.73 0.91 0.91 1.82 0 0
3.64 1.82 0 0 3.64 2.73
1.82 0 0.91 1.82 0 0.91
2.73 1.82 2.73 0.91 2.73 4.55
2 peaks that overlap any epigenetic marker from 0-50kb upstream of the TSS
measured in kilobases.
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downregulated genes and also associates with more mar-
kers of transcriptional activation and elongation.
Hierarchical and functional clustering of differentially
regulated genes by SYT- SSX2
In order to determine higher order relationships among
the histone modifications themselves and gene expres-
sion, and using the criterion that genes were included if
they contained a binding site for SYT-SSX2 that over-
lapped with at least 1 epigenetic marker, hierarchical
clustering was performed on the differentially regulated
genes. To do so, the degree of overlap between SYT-
SSX2 and a given modification was calculated as a ratio
of bases covered per 5kb bin upstream of the TSS or the
ratio of bases covered in the gene body over the total
number of bases in the coding sequence. This data gen-
erated a signature of modifications by distance for each
gene and was used in hierarchical clustering analyses.
Analysis of the upregulated genes corroborated earlier
results and identified H3K27me3 as the predominant
modification associated with SYT-SSX2 binding and
gene expression (Figure 4, top panel). The location and
extent of H3K27me3 was variable across all genes, but
there were 2 sub-clusters in which SYT-SSX2/
H3K27me3 intersecting sites were located within the en-
tire range of distances that we analyzed. The first of
those sub-clusters is highlighted in Figure 4 (top panel).
It has been reported previously that genes densely cov-
ered by H3K27me3 were involved in the differentiation
and development of alternate lineage pathways, thus we
wanted to determine the function of the genes within
this sub-cluster. Based on our previous analysis [26], we
found that 50% of these genes are involved in neural de-
velopment and function. To summarize, SYT-SSX2 oc-
cupies regions within and upstream of upregulated
genes that are enriched in H3K27me3. Functionally,
these genes can be subdivided based on the extent of
SYT-SSX2/H3K27me3 intersection and are in line with
our previous observation of the increased expression of
genes with neural characteristics.
Similar hierarchical clustering was performed on the
downregulated genes. This analysis led to the identifica-
tion of 2 clusters of genes with differential signatures.
The first is characterized by SYT-SSX2/H3K27me3 over-
lap from 0-10kb and 20-50kb upstream of gene TSS,
whereas the second cluster is marked by the overlap of
SYT- SSX2 with histone modifications related to tran-
scriptional activation at close ranges (Figure 4, bottom
panel). Interestingly, these two signatures appear to be
mutually exclusive. SYT-SSX2/H3K27me3 overlaps are
minimal or absent in the genes marked by close-range
SYT-SSX2 intersection with activating modifications and
vice versa (Figure 4, bottom panel). Additionally, unlikethe upregulated genes, which were functionally related
based on their clustering, the genes within these clusters
were not clearly associated with a particular pathway or
program. Together, these data suggest that SYT-SSX2-
mediated downregulation of gene expression occurs
through different mechanisms, one dependent on re-
cruitment by Polycomb and the other independent of
Polycomb.
Discussion
In this report we present evidence that the nuclear re-
cruitment of the SYT-SSX2 oncogene is a non-random
event and that it is directed to specific loci across the
genome. Polycomb-modified regions form the principal
targeting module for the SYT- SSX2 nuclear complex,
supporting earlier observations regarding the association
of the oncogene with Polycomb components [11,17,24].
In addition, a subset of the genes bound by SYT-SSX2
displayed alterations in expression. These genes were
typified by certain epigenetic attributes: upregulated
genes were characterized by the predominant association
of SYT-SSX2 with regions enriched with the Polycomb
marker H3K27me3, whereas downregulated genes could
be subdivided into at least 2 categories distinguished by
occupation of the fusion protein in regions displaying ei-
ther H3K27me3 enrichment at short- and long-ranges
or the presence of modifications associated with tran-
scriptional activation within the gene body or near the
TSS.
Our genome-wide analyses revealed that SYT-SSX2 is
targeted to over 3,000 genes, yet alterations in expres-
sion are noted for, at most, 740 of these targets. It is not
unprecedented that the number of binding sites for a
particular factor is far greater than the number of genes
that are differentially expressed when that factor is
induced, as was the case with the myogenesis regulator
MyoD [32], or the PAX3-FKHR fusion associated with
rhabdomyosarcoma [33]. These data also suggest that
additional signals may be required in order to produce
functional outcomes after binding to target loci. In sup-
port of this notion, phosphorylation of bound p53 upon
treatment with etoposide was required to alter gene ex-
pression [34]. In the same way, alterations in gene ex-
pression by SYT-SSX2 may require additional signaling
events that succeed its binding. The H3K27me3 modifi-
cation is catalyzed by PRC2, and it is known that PRC1
and PRC2 do not occupy completely identical sets of
genes within a given cell type [28,35]. As direct inter-
action of the fusion protein has only been seen with the
PRC1 component Ring1b [24], it follows that SYT-SSX2
will not associate with all H3K27me3-labeled regions.
Furthermore, PRC1 may also be recruited to chromatin
independently of PRC2 [25]. Recruitment of SYT-SSX2
by PRC1 could then explain at least some of the other
Figure 4 Hierarchical clustering of differentially regulated genes. Signatures for each differentially regulated gene were derived from the
extent of overlap between SYT-SSX2 peaks and the epigenetic markers within the gene body or in 5Kb bins upstream of the TSS up to -50Kb
(defined as coverage ratio; each bin has a coverage ratio for each epigenetic marker). Signatures were used as the input for hierarchical clustering
using Cluster 3.0. Heatmaps were generated using Java Treeview. Each row represents a gene, and each column represents an epigenetic marker
for a given bin (for example H3K27me3 from 0-5Kb or PolII in gene). Coverage ratios range from 0-1 with black squares representing bins with a
ratio of 0 and red squares representing a ratio of 1. Top panel: Clustering of upregulated genes. Inset is enlarged portion of the heat map, and
the epigenetic markers included in this region correspond to H3K27me3 at all distances and within the gene. Gene names are listed to the right.
Highlighted in red are genes that are involved in neural development and function. Bottom panel: Clustering of downregulated genes. Yellow
and blue ovals isolate 2 distinct clusters corresponding to genes with SYT-SSX2/H3K27me3 overlapping regions and SYT-SSX2 peaks overlapping
with modifications associated with transcriptional activation, respectively. The position and identity of the epigenetic marker(s) comprising a
particular cluster are listed to the right.
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Therefore, it would be interesting to determine the de-
gree of overlap between SYT-SSX2 ChIPSeq and
genome-wide binding patterns of PRC1 in C2C12 cells.
Additional signatures distinguished upregulated and
downregulated genes. Most genes with increased expres-
sion and marked by H3K27me3 had SYT-SSX2 binding
sites within their body or near their TSS, while greater
numbers of genes with decreased expression marked by
H3K27me3 are occupied at a distance. This dissimilarity
may reflect alternate mechanisms of Polycomb-mediated
silencing. For example, it has been reported that the
structure of PRC1 may differ when it is proximal to the
TSS versus when it is bound distally; functionally, this
results in opposite consequences on gene expression
after depletion of PRC1 components [36]. Therefore,
PRC1 dysfunction caused by SYT-SSX2 could result in
opposite effects. Another explanation may involve the
ability of SYT-SSX2 to interact with Brg1. In embryonic
stem (ES) cells, Brg1 tunes expression of Polycomb tar-
get genes resulting in either activation or enhanced si-
lencing, and so may augment repression rather than
antagonize it [37].
In addition, a second subcluster of downregulated
genes was characterized by the presence of histone mod-
ifications associated with active transcription within the
gene or proximal (0-5kb) to the TSS. Together with the
fact that close-range binding by SYT-SSX2 at Polycomb-
regulated genes results in gene activation, these data
indicate that proximal binding by the fusion protein
functions to antagonize the transcriptional status of tar-
get genes. Moreover, previous work has indicated that
these are both consequences of aberrant Polycomb func-
tion since SYT-SSX2 has been shown both to antagonize
and to initiate Polycomb silencing [23,24]. In this way,
SYT-SSX2 may act as a switch protein that generally
opposes the gene expression profile of the cell.
Clustering of neuronal genes occupied by SYT-SSX2
and enriched with H3K27me3-marked chromatin pro-
vided a link to the mechanism of proneural lineage acti-
vation by the oncogene [26]. More specifically, it begins
to explain how dictation of the neuronal program at the
expense of commitment to the normal mesenchymal
lineages might have taken place. In a recent report on
the epigenetic landscape during myogenic differentiation
of the C2C12 myoblasts, gene subsets pertaining to per-
manently silenced programs including neurogenesis
appeared to be held in check by an abundance of modi-
fied histone H3K27me3, reflecting stable silencing by
Polycomb [28]. They represent non-mesodermal lineages
whose activation during myogenesis would be inappro-
priate and disruptive to the myoblast. Intriguingly, these
programs are believed to be distinctly regulated by
PRC1, and are not influenced by PRC2 [28]. SYT-SSX2has so far been shown to specifically deregulate the si-
lencing function of the Bmi/Ring1 E3-ligase of PRC1
[24]. It follows that SYT-SSX2 may be recruited to
H3K27me3 sites by PRC1, resulting in the untimely acti-
vation of PRC1-controlled lineages such as neurogenesis.
Further investigations into the mechanism of PRC1 an-
tagonism upon recruitment of SYT-SSX2 and the factors
involved are needed to clarify how the neuronal lineage
is activated and the extent of its contribution to normal
differentiation block and initiation of tumorigenesis.
Additional mechanisms can explain the specificity for
the upregulation of neural genes. The first involves the
endogenous expression of certain factors that makes a
particular outcome more likely in one cell versus a dif-
ferent type. It is hypothesized that expression is the re-
sult of the balance between Polycomb and Trithorax
activity at a given gene, and some cell types may possess
additional regulators that can affect gene expression
once that balance has been perturbed [38,39]. C2C12
cells may then express certain factors that could guide
the expression of neural genes. One potential factor is
the REST/NRSF transcriptional repressor that silences
neural genes in alternate lineages. Inhibition of its activ-
ity leads to neurogenesis in C2C12 cells so misexpres-
sion of its target genes by SYT-SSX2 may result in the
ectopic neural program seen in these cells [40]. In a pre-
cedent example, SYT-SSX was reported to cause aber-
rant expression of E-cadherin by interacting with either
of the tissue-specific transcriptional repressors Snail or
Slug [41]. This suggested that interaction with repressor
molecules directs gene activation by the fusion.
An alternate mechanism may involve the activation of
tissue-specific enhancer elements. In ES cells, enhancers
that control the expression of inactive genes involved in
differentiation of multiple lineages are labeled by
H3K27me3 and H3K4me1. When these elements be-
come active K27 becomes acetylated, a modification that
can be catalyzed by p300 [42,43]. Recruitment of SYT-
SSX2 to these elements by interactions with Polycomb
may lead to increased acetylation of K27 by p300 result-
ing in their activation and subsequent perturbations in
the balance between silencing and expression.
These data allow us to propose a model of recruitment
and regulation of target gene expression by SYT-SSX2.
In the case of upregulated genes, the fusion protein is
recruited by interactions with PRC1, and gene activation
is determined by the presence of lineage-specific tran-
scription factors or the activation of specific enhancer
elements (Figure 5A). For downregulated genes, SYT-
SSX2 may be recruited by PRC1 or PRC2 at a distance
from target promoters (Figure 5B, top) or directly tar-
geted to active genes (Figure 5B, bottom). Recruitment
may occur through interactions with the modified his-
tones themselves, the complexes that catalyze those
Figure 5 Models of SYT-SSX2 recruitment and activity. A)
Model of recruitment and activity at an upregulated gene. SYT-SSX2
is recruited primarily to silent genes involved in the specification of
other lineages by interactions with Polycomb Repressive Complexes
(PRC1, dark blue oval; PRC2, light blue oval). In the presence of
certain lineage-specific transcription factors (LSTF, red oval) and/or
by interaction with lineage-specific enhancers (Enhancer, orange
rounded rectangle), SYT-SSX2 association with the gene results in
transcriptional activation. B) Model of recruitment and activity at a
downregulated gene. Top) SYT-SSX2 may be recruited by
interactions with Polycomb Repressive Complexes at a distance from
the gene TSS. The gene itself is marked by activating histone
modifications (Active, pink circle), and due to the presence of other
regulators (?, black rounded rectangle), SYT-SSX2 carries out
transcriptional silencing. Bottom) SYT-SSX2 may be directly recruited
to the proximal regulatory region through association with
activating histone modifications or other unidentified factors. These
other factors also provide a signal to SYT-SSX2 such that it mediates
repression.
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specific transcription factors. The presence of other fac-
tors is likely to be important in specifying target genes
for repression.Conclusions
The data described here provide a foundation for unco-
vering the mechanism of SYT-SSX2 recruitment. The
preeminent association of SYT-SSX2 with H3K27me3
indicates that the fusion protein does not simply target
to regions of open chromatin by default, but it occupies
a subset of Polycomb loci. Most importantly, this ana-
lysis has revealed that nuclear programs stably silenced
by Polycomb complexes in any mesenchymal precursor
cell could potentially constitute the primary target for
deregulation by SYT-SSX2. It provides a justification for
the apparent dominant effect of the oncogene in itstarget cells and the ability of synovial sarcoma to arise in
multiple sites of the body.
As binding of SYT-SSX2 does not completely correlate
with changes in gene expression, additional targeting fac-
tors, genetic or epigenetic, as well as specific extracellular
signals are most likely necessary to provide the proper
stimulus for activation of distinct gene subsets and the
generation of distinct cell fates. Thus, genes that are
bound by SYT-SSX2 but whose expression is unaltered
may be poised for activation in response to certain signal-
ing events. Indeed, the dependence of the neural pheno-
type on FGF signaling supports such a scenario [26].
This analysis sets the stage for key developments to-
ward the full understanding of how SYT-SSX2 redirects
a heritable fate in the undifferentiated stem cell and
identifying the factors and the extrinsic and intrinsic sig-
nals involved in this process. The Polycomb proteins are
important regulators of gene expression in development
as well as cancer, and much attention has focused on the
mechanism through which these proteins regulate differ-
entiation and contribute to tumorigenesis. One aspect of
Polycomb function that has not been addressed exten-
sively is how the activity of these proteins is regulated.
As deregulation of Polycomb activity seems to be at the
heart of SYT-SSX2 function, the differential binding pat-
terns and their correlation with gene expression
described in this report provide a unique opportunity to
examine this process in detail.
Moreover, as the fusion protein demonstrated a pro-
pensity to target the stem cell signaling network [35],
the manner in which these pathways regulate Polycomb
function can also be explored. Elaborating how SYT-
SSX2 targets and controls a specific program will clarify
how to change the epigenetic structure of one cell to
that of an alternate lineage. Ultimately, this will improve
the efficiency of cellular reprogramming, and more im-




All microarray and ChIPSeq data are available at the
Gene Expression Omnibus (available at www.ncbi.nlm.
nih.gov/geo/; [44]) accessions GSE26562 (C2C12 micro-
array), GSE26563 (hMSC microarray, GSE26564 (SYT-
SSX2 ChIPSeq), and GSE26565 (accession for all
datasets).
Previously published ChIPSeq datasets for ubiquity-
lated histone H2B (H2BUb); mono-, di-, and trimethy-
lated histone H3 lysine 4 (H3K4me1/2/3); acetylated
histone H3 lysine 9 (H3K9Ac), lysine 18 (H3K18Ac), and
histone H4 lysine 12 (H4K12Ac); trimethylated histone
H3 lysine 27 (H3K27me3) and lysine 36 (H3K36me3);
and RNA polymerase II (PolII) were downloaded from
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http://www.biomedcentral.com/1471-2164/13/189the Gene Expression Omnibus (GEO) accession
GSE25308 [28]. MeDIP-ChIP data were obtained from
GEO accession GSE22077 [45]. Overlapping regions be-
tween individual datasets and SYT-SSX2 were deter-
mined using the Coverage and Intersect tools from the
Galaxy program (available at http://main.g2.bx.psu.edu/)
[46-48].Association of SYT-SSX2 ChIPSeq peaks with gene
expression
SYT-SSX2 peaks were annotated to the nearest down-
stream gene on both strands by measuring the distance
from the 5’ end of the peak to the gene transcription
start site (TSS). Peaks associated with differentially
expressed genes were identified.Hierarchical clustering
Differentially regulated genes containing overlapping
sites between SYT-SSX2 and specific epigenetic markers
within the gene and up to 50kb upstream of the TSS
were used in the clustering analysis. For each gene,
coverage ratios (the number of bases covered by overlap-
ping regions divided by the total number of bases in a
given window) for the gene body and for 5kb bins up-
stream of the TSS (up to 50kb) were calculated for each
epigenetic marker. These coverage ratios served as the
input data for the clustering analysis. Hierarchical clus-
tering was performed separately for up- and downregu-
lated genes using Cluster 3.0 [49] with gene and array
clustering. The similarity metric used was Spearman
Rank Correlation, and the clustering method used was
centroid linkage. The output file was uploaded to Java
Treeview [50] for visualization. Heat map images were
downloaded from Java Treeview.Additional file
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